Why the study?
Mortality in acute myocardial infarction complicated by cardiogenic shock remains high, yet evidence-based scientific knowledge is limited, leaving recommendations largely reliant on registry data and extrapolations.
Provides a consensus position statement and clinical practice advice for managing acute myocardial infarction complicated by cardiogenic shock.
Guides immediate AMI-cardiogenic shock management; extends prior ESC guidance with focused acute care consensus.
Most of the guideline-recommended treatment strategies for patients with acute coronary syndromes have been tested in large randomised clinical trials. Still, a major challenge is represented by patients with acute myocardial infarction admitted with impending or established cardiogenic shock. Despite early revascularization the mortality of cardiogenic shock remains high and roughly half of patients do not survive until hospital discharge or 30-day follow-up. However, there is only limited evidence-based scientific knowledge in the cardiogenic shock setting. Therefore, recommendations and actual treatments are often based on retrospective or prospective registry data and extrapolations from randomised clinical trials in acute myocardial infarction patients without cardiogenic shock. This position statement will summarise the current consensus of the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock based on current evidence and will provide advice for clinical practice.
No takes yet. Share an insight, caveat, or question.
Zeymer et al. (2020) conducted a review in Acute myocardial infarction complicated by cardiogenic shock. Diagnosis and treatment strategies was evaluated. This position statement provides consensus recommendations for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: